Agilent Technologies Expands Presence in DNA Microarray Market Through Alliance With Rosetta Inpharmatics.Business/Technology Editors PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif.--(BUSINESS WIRE)--Feb. 29, 2000 Licensing Agreement With Rosetta Inpharmatics Will Enable Agilent To Alter the Landscape of the Microarray See micro array. microarray - A technique for performing many DNA experiments in parallel. Nothing to do with computers. Market for Accelerated Gene-Based Life Science Research and Development Agilent Technologies This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , Inc. (NYSE NYSE See: New York Stock Exchange : A) today announced the expansion of its alliance with Rosetta Inpharmatics Inc. to include Rosetta's FlexJet DNA microarray DNA microarray A small solid support, usually a membrane or glass slide, on which sequences of DNA are fixed in an orderly arrangement. DNA microarrays are used for rapid surveys of the expression of many genes simultaneously, as the sequences contained on a technology. This announcement follows an earlier agreement between the two companies to develop and distribute Rosetta's gene-expression analysis software platform, the Rosetta Resolver Expression Data Analysis System, and extends Agilent's commitment to become a major provider to the DNA microarray analysis market. "Agilent is committed to reshaping the gene-expression market to enable scientific innovation. Our ongoing relationship with Rosetta marks our dedication to provide tools and solutions to substantially accelerate the adoption and value of genomics-based information by the pharmaceutical and agrochemical agrochemical Any chemical used in agriculture, including chemical fertilizers, herbicides, and insecticides. Most are mixtures of two or more chemicals; active ingredients provide the desired effects, and inert ingredients stabilize or preserve the active ingredients or aid industry worldwide," said Ned Barnholt, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Agilent. "This technology adds a critical component to Agilent's complete gene-expression technology suite." As a complement to its own inkjet array technology used to develop catalog catalog, descriptive list, on cards or in a book, of the contents of a library. Assurbanipal's library at Nineveh was cataloged on shelves of slate. The first known subject catalog was compiled by Callimachus at the Alexandrian Library in the 3d cent. B.C. type arrays, Agilent will further develop, manufacture and distribute the FlexJet arrays. These array technologies offer flexibility in gene content and fast turn-around time, which can be used to develop low-cost arrays -- designed to customer requirements -- in a matter of days. "This collaboration marries the best gene expression technology with one of the largest manufacturing and marketing capabilities in the life sciences industry," said Stephen Friend, M.D., Ph.D., president and chief scientific officer of Rosetta Inpharmatics, Inc. "Agilent's plans to open the rapidly growing expression market to a wider group of users will ultimately move DNA microarray use beyond research labs and into medical diagnostics and other clinical applications." Rosetta's FlexJet DNA microarrays and Resolver software, coupled with Agilent's strengths in biology, computation, inkjet technologies and engineering provide a complete solution to understanding the function of genes within human, animal and plant cells. This knowledge will better enable scientists to identify and prioritize pri·or·i·tize v. pri·or·i·tized, pri·or·i·tiz·ing, pri·or·i·tiz·es Usage Problem v.tr. To arrange or deal with in order of importance. v.intr. novel drug and agrochemical targets and to predict drug toxicity faster, more accurately, and more cost effectively. In December 1999, Agilent and Rosetta announced an alliance to provide and further develop the Rosetta Resolver, an enterprise-wide, gene-expression, bioinformatics solution for the pharmaceutical, biotechnology, and agriculture industries. Agilent will distribute the Rosetta Resolver system through its worldwide pharmaceutical distribution channel of its Chemical Analysis Group. Under the terms of the agreement, Agilent made an equity investment in Rosetta Inpharmatics. The two companies expect to jointly invest $75 million over a three-year period. Information about Agilent's chemical analysis products and services can be found on the Web at www.agilent.com/chem. About Rosetta Inpharmatics Rosetta Inpharmatics, Inc., is a leading bioinformation company with a focus on gene expression technology. The company's integrated technologies and services permit researchers to fully explore the diverse causes and consequences of changes in gene expression, and to focus on those cellular processes that are specifically affected by disease, exposure to pharmaceuticals, chemicals, environmental conditions or genetic engineering. The Company's integrated platform comprises design and analysis of proprietary DNA microarrays, a powerful, flexible informatics Same as information technology and information systems. The term is more widely used in Europe. system, and advanced molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller techniques to support the expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, programs of pharmaceutical, biotechnology, agrochemical, and ag--biotech companies. The Rosetta platform is economical, reliable, and flexible -- ideally suited to meet today's target, pathway, drug, and agrochemical discovery needs. Information about Rosetta can be found on the world wide web at http://www.rii.com. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a diversified technology company, resulting from Hewlett-Packard Company's plan to strategically realign re·a·lign tr.v. re·a·ligned, re·a·lign·ing, re·a·ligns 1. To put back into proper order or alignment. 2. To make new groupings of or working arrangements between. itself into two fully independent companies. With 42,000 employees serving customers in more than 120 countries, Agilent Technologies is a global leader in designing and manufacturing test, measurement and monitoring instruments, systems and solutions, and semiconductor and optical components. The company serves markets that include communications, electronics, life sciences and healthcare. The businesses comprising Agilent, a subsidiary of HP, had net revenues of more than $8.3 billion in fiscal year 1999. Information about Agilent Technologies can be found on the Web at www.agilent.com. Resolver is a U.S. trademark of Rosetta Inpharmatics |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion